Samsung Bioepis headquarters in Incheon / Courtesy of Samsung Bioepis
Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp.
The product, Ustekinumab BS 45 mg Syringe for S.C. Injection “NIPRO,” was listed under Japan’s National Health Insurance (NHI) drug price standard following an Official Gazette announcement on Tuesday, becoming effective the same day.
The launch represents Samsung Bioepis’ entry into the Japanese biosimilars market through its collaboration with Nipro.
“We are thrilled to announce the launch of our first biosimilar product in Japan in partnership with Nipro,” said Chung Jin-han, vice president and head of commercial strategy for international markets at Samsung Bioepis.
